Kymera rises as Gilead pays $45 million for experimental cancer drug

Kymera Therapeutics

09/04/2026 12:20

** Shares of biotech firm Kymera Therapeutics KYMR.O rise 3% to $89.50 premarket

** Co says it will receive $45 million upfront from Gilead Sciences GILD.O to license KT-200, an experimental oral cancer drug

** KT-200 targets CDK2, a protein that helps tumors grow; the drug is designed to remove the protein entirely, which could improve effectiveness and reduce side effects - KYMR

** Co says the drug could help treat hard‑to‑treat cancers such as advanced breast cancer, where treatment options are limited

** Adds that Gilead gets global rights and will lead further development, aiming to start human studies in 2027

** Says Kymera could receive up to $750 million in total payments plus royalties if the drug is approved

** As of last close, stock up ~12% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))